BioStock: Idogen’s acting CEO talks about the plans for the autumn

Christina Herder has been appointed new acting CEO by the board of directors. Herder has for the past five years been a board member of Idogen and also has more than 30 years of experience in several senior positions in the pharmaceutical industry. BioStock talked to Christina about the potential for Idogen’s cell therapy and the company’s plans for the autumn.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/idogens-acting-ceo-talks-about-the-plans-for-the-autumn/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se